Hypoxic-ischemic encephalopathy (HIE) in neonates is a significant cause of neonatal morbidity, mortality, and long-term neurodevelopmental impairment (NDI). Hence, it demands effective, evidence-based therapeutic interventions. Therapeutic hypothermia (TH) has been proven to be effective in reducing mortality and morbidity associated with HIE in many randomized controlled trials [
1,
2]. Studies have also shown that TH reduces oxidative stress and DNA damage among infants who sustained perinatal asphyxia [
3,
4]. TH has been shown to decrease NDI and the risk of cerebral palsy in infants with HIE [
4]. The outcomes vary depending on the specific settings where it is implemented [
5]. While HT has become the standard of care in the management of neonatal HIE, its limitations in failing to uniformly improve outcomes for all infants with HIE have necessitated the exploration of additional neuroprotective strategies [
6]. …